Figure 13

Improved erection (GEQ-Q1): Type II diabetes.

Figure 14

The mean IIEF-Q3 score: Type I-II diabetes.

Figure 17

Any adverse events (treatment-related): Type II diabetes.

Efficacy. Proportion of participants with improved erection, GAQ-Q1, mean IIEF-Q3/4 score. The pooled effect estimates of meta-analyses of diabetic patients were all statistically significant, favoring the use of sildenafil over that of placebo to improve the erection (GEQ-Q1) in both Type I and II (RR = 4.25; 95 percent CI: 2.60– 6.93) as well as only in Type II patients, (RR = 5.33, 95 percent CI: 3.89–7.29). The pooled effect estimates for penile penetration ability (IIEF-Q3) (WMD: 1.03, 95 percent CI: 0.34–1.73) and erectile maintenance frequency (IIEF-Q4) (WMD: 1.15, 95 percent CI: 0.74–1.55) were also statistically significant in favor of sildenafil (Figures 12–15).